Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gaston Habets

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Proceedings of the National Academy of Sciences of the United States of America|January 1, 2009
Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agentDean R Artis, Jack J Lin, Chao Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 22, 2008
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityJames Tsai, John T Lee, Weiru Wang, et al.
Nature|September 9, 2010
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaGideon Bollag, Peter Hirth, James Tsai, et al.
The New England Journal of Medicine|July 30, 2015
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell TumorWilliam D Tap, Zev A Wainberg, Stephen P Anthony, et al.
Cancer Discovery|February 2, 2018
BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET InhibitorHatice Gulcin Ozer, Dalia El-Gamal, Ben Powell, et al.
The New England Journal of Medicine|January 20, 2012
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitorsFei Su, Amaya Viros, Carla Milagre, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Proceedings of the National Academy of Sciences of the United States of America|January 1, 2009
Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agentDean R Artis, Jack J Lin, Chao Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 22, 2008
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityJames Tsai, John T Lee, Weiru Wang, et al.
Nature|September 9, 2010
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaGideon Bollag, Peter Hirth, James Tsai, et al.
The New England Journal of Medicine|July 30, 2015
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell TumorWilliam D Tap, Zev A Wainberg, Stephen P Anthony, et al.
Cancer Discovery|February 2, 2018
BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET InhibitorHatice Gulcin Ozer, Dalia El-Gamal, Ben Powell, et al.
The New England Journal of Medicine|January 20, 2012
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitorsFei Su, Amaya Viros, Carla Milagre, et al.
Pageof 2